已收盤 11-06 16:00:00 美东时间
+0.261
+1.17%
Immutep focuses on advancing efti for HNSCC (CPS <1) and neoadjuvant STS, with trials targeting H2 CY27. IMP761, an anti-LAG-3 antibody for autoimmune diseases, is now a co-priority and will be featured at ACR 2026. The root cause analysis of TACTI-004 identified structural differences in efti manufacturing scales, leading to a new 200 L scale production. The company received A$0.86 million from Australia’s R&D Tax Incentive and €1.36 million fro...
10-29 12:00
香港联交所最新数据显示,9月9日,INSIGHTZEN TECHNOLOGY LIMITED减持大同集团(00544.HK)250万股,每股作价2港元,总金额为500万港元。
10-20 19:20